Evaxion's EVX-05 Breakthrough: Riding the Personalized Vaccine Wave

A new glioblastoma program, a validating Phase III from Moderna/Merck, and a cash runway that holds—all in one quarter.

EVAX · Earnings Call · 2026-08-20

At its Q2 2026 update, Evaxion A/S unveiled a data-packed quarter that could reposition the small-cap biotech. The company announced a new off-the-shelf cancer vaccine program, EVX-05, targeting glioblastoma, alongside a validation from the broader field that may finally unlock partnering discussions. Here's what changed and why it matters.

A New Pipeline Pillar: EVX-05

The most tangible shift is the introduction of EVX-05, a conserved-antigen vaccine for glioblastoma developed with Duke University. In her prepared remarks, CFO/COO Birgitte Rono detailed the approach: "So in collaboration with Duke University, we are developing an off-the-shelf vaccine, EVX-05 for glioblastoma or GBM, targeting conserved antigens as announced earlier this week." “The target selection process allows for broad tumor coverage despite immune and tumor antigen differences across patients.” — Birgitte Rono, Chief Financial Officer (CFO) and Chief Operating Officer (COO) · 2026-08-20 This is a direct extension of the platform's ERV-based technology, which the company has been quietly advancing. The new program complements EVX-04, which targets AML and is on track for a regulatory filing by year-end. In Q&A, Rono elaborated on the Duke collaboration: “So the collaboration with Duke has been ongoing for quite some time. They do have a lot of sequencing data from the patients that they're treating in their clinic.” — Birgitte Rono, Chief Financial Officer (CFO) and Chief Operating Officer (COO) · 2026-08-20 This gives Evaxion a unique data moat in a difficult-to-treat cancer.

The Field's Turning Point

The biggest macro catalyst came from outside the company. On the day before the call, Moderna and Merck announced positive Phase III data for their personalized neoantigen vaccine in melanoma. CEO Helen Tayton-Martin captured the significance:

And obviously, it was a great day for the field yesterday to see the positive Phase III results from the similar Moderna and Merck program in personalized cancer vaccine in melanoma produced.
Helen Tayton-Martin, Chief Executive Officer (CEO) · 2026-08-20

For Evaxion, this validation is more than a morale boost; it removes a key objection in partnering discussions. As Rono noted, "we can definitely say that the field is moving from promising experimental immunotherapy towards a clinically validated therapeutic modality." “These data are not just only a win for Moderna and Merck, but it's a win for the entire field as they broadly validate the personalized neoantigen vaccine concept.” — Birgitte Rono, Chief Financial Officer (CFO) and Chief Operating Officer (COO) · 2026-08-20 The company also received a second Galien UK Award for its AI-Immunology platform, further legitimizing its technology. Birgitte Rono had previously touted the platform's hit rate in March: “with this 81% hit rate, as we call it, I think this is very impressive.” — Birgitte Rono, Head of R&D or similar senior R&D role · 2026-03-06

Financial Discipline and the Path Ahead

Despite the pipeline expansion, Evaxion keeps its cash runway intact. CFO Thomas Schmidt confirmed a net loss of $3.7M for Q2 and a cash position of $14M, reaffirming the runway into the second half of 2027. “We are again reconfirming our cash runway, and the equity that we also have reflects the result for the first 6 months.” — Thomas Schmidt, Chief Financial Officer (CFO) · 2026-08-20 He also disclosed activation of the ATM facility to capture the positive momentum. The company's disciplined resource allocation remains a recurring theme, but the new EVX-05 program adds a growth option without near-term funding pressure. The story here is one of timing: a small biotech with a validated platform, a new high-profile program, and an external market tailwind. The key question is whether the Moderna validation accelerates a partnership. Helen Tayton-Martin hinted at active negotiations: “So I've been doing BD for 20-odd years and things can go very fast when there's motivation and competition.” — Helen Tayton-Martin, Chief Executive Officer (CEO) · 2026-08-20 That quote echoes her earlier statements in May: “We would anticipate that that will be something that we will be partnering.” — Helen Tayton-Martin, Chief Executive Officer · 2026-05-07 The company now has more to offer—both a second asset and a de-risked field.